The FDA has approved a new daily pill called FOUNDAYO to help adults manage their weight.

The U.S. Food and Drug Administration (FDA) has approved a new prescription medicine called FOUNDAYO (orforglipron) for chronic weight management. It is a daily pill that works as a GLP-1 receptor agonist, a type of medicine that helps regulate appetite and blood sugar. It is approved for use along with a reduced-calorie diet and increased physical activity to help adults reduce excess body weight and keep it off over the long term. This approval is specifically for adults with obesity, or for adults who are overweight and have at least one weight-related health issue, such as high blood pressure or high cholesterol. The approval of FOUNDAYO means there is now a new oral option available in the established GLP-1 medicine class for weight management. Until now, many medicines in this group have been injections. Having a pill form may be a helpful alternative for some people and their doctors to consider when discussing treatment plans. It's important to remember that this medicine was studied in clinical trials over 72 weeks where all participants also followed a lifestyle program. The label also advises that it should not be used at the same time as another GLP-1 medicine. As with any new treatment, it is a significant step that provides another choice, but it is not a standalone solution. A key point for patients is that this news does not change the fundamental importance of talking with a healthcare provider. Only a doctor who knows your full health history can determine if a treatment like this is appropriate and safe for your individual situation. They can help you understand the potential benefits and risks in the context of your overall health goals.